OnKure Therapeutics, Inc. (NASDAQ:OKUR) Given Consensus Recommendation of “Hold” by Analysts

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have earned a consensus recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $32.00.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of OnKure Therapeutics in the 2nd quarter valued at about $25,000. Bailard Inc. bought a new stake in OnKure Therapeutics in the second quarter valued at approximately $34,000. Jane Street Group LLC purchased a new stake in shares of OnKure Therapeutics during the fourth quarter valued at approximately $56,000. Barclays PLC grew its holdings in shares of OnKure Therapeutics by 4,286.8% in the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after purchasing an additional 26,621 shares during the last quarter. Finally, Rangeley Capital LLC bought a new position in shares of OnKure Therapeutics in the second quarter worth approximately $71,000. 90.98% of the stock is owned by institutional investors.

OnKure Therapeutics Stock Performance

OKUR stock opened at $3.04 on Friday. The company has a market capitalization of $41.19 million, a price-to-earnings ratio of -0.63 and a beta of 0.45. The stock has a fifty day moving average of $2.77 and a 200-day moving average of $2.84. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.32.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.